Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

This article discusses hair loss conditions and available camouflage options after medical and surgical interventions fail, but it reports no new clinical findings.

This chapter reviews trichoscopic-pathologic correlations in Frontal Fibrosing Alopecia and reports no new clinical results; the authors discuss genetics, clinical patterns, and unusual variants associated with this condition.

This article presents the surgical technique of long hair follicular unit excision (FUE) in hair transplantation and reports procedural and outcome data for 134 patients, without evaluating clinical outcomes.

The woman's skin and hair symptoms were confirmed as frontal fibrosing alopecia, and while facial papules are common in such cases, there's no effective local treatment, but systemic treatments can help.

FUE is a minimally invasive hair transplant method using various donor sites.

This resource outlines the focus areas of the Madridge Journal of Dermatology & Research and reports no new clinical findings.

This article discusses the DOAJ, a comprehensive index of international open access journals, and emphasizes its role in providing free quality content online without presenting new research findings.

Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.

Papular mucinosis can cause eyebrow hair loss, but treatment can lead to regrowth.

This article discusses the history of modern hair restoration surgery beginning with Dr. Norman Orentreich's introduction of the macrograft technique in 1959 and reports no new clinical results.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

In two phase 3 clinical trials, this study found that adults with severe alopecia areata receiving baricitinib experienced significant hair regrowth on the scalp, eyebrows, and eyelashes over 36 weeks compared to placebo, although longer-term data are needed to fully assess benefits and risks.

The instruments are valid but don't fully capture the emotional impact on adolescents with alopecia areata.

This article reviews both minimally invasive and surgical procedures used to treat periorbital aging, highlighting advancements in rejuvenation techniques for areas like the eyebrows and eyelids.

This review discusses frontal fibrosing alopecia, noting its frequent misdiagnosis and highlighting the need for larger studies to better understand its epidemiology, causes, and treatment options; it reports no new clinical findings.

In this case report, treatment with corticosteroid and cyclosporine improved hair growth in a 19-year-old male with alopecia universalis over 51 days.

This case report presents a 14-year-old girl with both type I diabetes and monilethrix, detailing her symptoms and treatment with topical minoxidil, while exploring a possible genetic link between the conditions.

A woman's hair grew back while she was taking sulphasalazine for arthritis.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

This case report described a 16-year-old girl with trichotillomania, highlighting the challenges in diagnosing the condition due to its similarity with alopecia areata and the sociocultural barriers preventing acceptance of psychiatric treatment.

This study found that oral JAK inhibitors significantly improve hair regrowth in adults with moderate-to-severe alopecia areata compared to placebo, although they are associated with a higher risk of non-serious adverse events.

This review discusses current research on cosmetic formulations, especially those involving dihydroquercetin combined with other compounds, for promoting eyelash and eyebrow growth, noting challenges with solubility and bioavailability and the potential need for further studies to validate efficacy and safety.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

This study found that patients with chronic, persistent alopecia areata experience significant psychosocial impairments unrelated to scalp hair loss, which influence their decision to start systemic therapy.

This retrospective case series reported that pediatric patients with alopecia totalis and subtotalis experienced significant hair regrowth after treatment with the JAK inhibitor upadacitinib, with mild acne as the most common side effect; however, larger studies are needed to establish its efficacy and safety conclusively.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

Dynaplast tape reduces swelling after hair transplants effectively.

This case study reports on a 72-year-old woman with frontal fibrosing alopecia and hair repigmentation, suggesting the rare occurrence of canities reversal could aid in diagnosing FFA.